Sharetreck – Tracking Genomic Investments & clinical trials for HIV.

In the dynamic landscape of cancer research, Memorial Sloan Kettering Cancer Center (MSK) continues to lead the charge with groundbreaking discoveries that not only redefine cancer treatment but also shed light on the intricacies of disease mechanisms. This blog post explores MSK’s recent paradigm-shifting findings, highlighting advancements in cancer therapy while acknowledging the challenges faced in the ever-evolving field of immunotherapy.

MSK’s exploration into the genetic element LINE-1 (also known as L1) has been nothing short of revelatory. LINE-1 is a family of related class I transposable elements found in the DNA of some organisms, classified with the long interspersed elements (LINEs). The acronym LINE comes from Long INterspersed Elements. Benjamin Greenbaum, Ph.D., and colleagues provided insights into LINE-1’s role in cancer by elucidating the X-ray crystallography structure of ORF2p, a key enzyme in LINE-1 activity. This structural understanding not only opens doors for novel treatments but also reveals crucial insights into viral mimicry within our genome, marking a significant leap in our understanding of cancer biology.

L1 activity, observed in numerous types of cancers, particularly manifests with extensive insertions found in colorectal and lung cancers. This revelation underscores the significance of MSK’s research in uncovering potential treatment targets within LINE-1, presenting a promising avenue for advancing cancer therapeutics.

SON: A Key Regulator of Blood-Forming Stem Cells

Collaborative efforts between MSK and the New York Genome Center uncovered SON, a large Ser/Arg (SR)-related protein with far-reaching implications. Also known as BASS1 or NRE-binding protein, SON serves as a splicing co-factor contributing to efficient splicing within cell cycle progression. Essential for maintaining genome stability and ensuring the efficient RNA processing of affected genes, SON also facilitates the interaction of SR proteins with RNA polymerase II. Its role in processing weak constitutive splice sites holds strong implications in cancer and other human diseases.

Led by Hanzhi Luo, PhD, and Mariela Cortés-López, PhD, the study on SON highlighted its impact on stem cell fate and its role in controlling inflammation. Understanding SON’s multifaceted function not only offers potential avenues for expanding stem cell populations but also provides critical insights into the effects of cancer treatments, underscoring the interconnected nature of cancer and RNA processing.

Immunotherapy Advancements Targeting CD47

Juan Osorio, MD, and the team’s study targeting the CD47 protein represents another milestone in MSK’s immunotherapy advancements. Novel antibodies exhibited heightened efficacy in identifying and eliminating CD47-expressing cancer cells in mice, signaling a promising technique for future clinical trials and offering potential long-term systemic antitumor immunity.

Navigating Challenges: FDA Reservations on Autologous CAR-T Therapies

While celebrating these strides in cancer research, it’s crucial to acknowledge challenges. The FDA’s reservations on Autologous CD19 and BCMA based CAR-T therapies highlight the need for careful consideration. The high cost of these therapies prompts reflection on how to make them widely available without disincentivizing crucial research and risk-taking in gene therapies.

Conclusion: Memorial Sloan Kettering Cancer Center’s groundbreaking research not only holds promise for improved cancer treatments but also unravels the intricate mechanisms governing diseases. These discoveries usher in a new era of precision medicine and therapeutic strategies. As we navigate the delicate balance between innovation and accessibility, MSK’s relentless pursuit of knowledge continues to shape the future of cancer treatment and our understanding of its complexities.